Antiretroviral therapy during pregnancy. Beyond AZT (ZDV).
Although zidovudine (ZDV) monotherapy remains the standard for the prevention of mother-to-child transmission, it may now be inadequate therapy for treatment of the mother. The safety and efficacy of the newer therapeutic agents have yet to be established during pregnancy; however, the need to maintain maternal health mandates that clinicians understand the benefits and limitations of antiretroviral therapy beyond ZDV.
Dattel
B J
BJ
Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, USA.
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000635:transmission; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors